Figure 3


a.
% cell viability
Variance Component
Large
Moderate
Small
Cabergoline
Ketoconazole
Roscovitine
GANT61
Pasireotide
Mifepristone
Etomidate
Mitotane
Metyrapone
Osilodrostat
b.
Decitabine
Enzalutamide
Belinostat
Tretinoin
Cladribine
Romidepsin
Cabergoline
Metyrapone
Methotrexate
Osilodrostat
Imiquimod
Vandetanib
Apalutamide
Vismodegib
Pentostatin
Mode of Action
DNA hypomethylation
Adnrogen receptor signaling inhibitor
Pan-Histone deacetylase (HDAC) inhibitor
Unknown
Inhibition of DNA synthesis and repair
Inhibition of PI3K/AKT signaling
Dopamine receptor antagonist
Inhibition of cortisol steroidogenesis
Inhibition of DNA synthesis and repair
Cortisol synthesis inhibitor
Stimulation of innate and acquired immunity
EGFR, RET, VEGFR inhibitor
androgen receptor antagonist
Hedgehog path inhibitor, smoothened receptor antagonist
Nucleic acid synthesis inhibitor
c.
Lomustine
Mifepristone
Mubritinib
Pralatrexate
Temozolamide
Plerixafor
Nivolumab
ipilimumab
GANT61
Enasidenib
Crizotinib
Rucaparib
Ixazomib citrate
Afatinib
Bortezomib
Axitinib
Trifluridine
Bleomycin
Mode of Action
Induces DNA damage
Glucocorticoid and progest. receptor antag.
HER2 tyrosine kinase inhibitor
Dihydrofolate reductase (DFHR) inhibitor
DNA alkylating agent
CXCR4 inhibitor
Immune checkpoint inhibitor
Immune checkpoint inhibitor
GLI1/Hedgehog signaling pathway inhibitor
isocitrate dehydrogenase inhibitor
ALK tyrosine kinase receptor inhibitor
PARP inhibitor
EGFR, HER2, HER4 inhibitor
26S proteosome inhibitor, induces cell apoptosis
VEGFR1, 2 and 3 inhibitor
Thymidine-based nucleoside metabolic inhibitor
Inhibition of DNA synthesis
d.
hPITO28
hPITO33
hPITO34
hPITO35
% Cell Viability
Log Concentration (nM)
e.
hPITO28
hPITO33
hPITO34
hPITO35
% Cell Viability
Log Concentration (nM)
f.
hPITO37
hPITO37N
hPITO38
hPITO38N
% Cell Viability
Log Drug Concentration (nM)